Hangzhou Beidou Biotechnology

Hangzhou Beidou Biotechnology is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, focused on the research and development of next-generation CAR-T cell therapies for solid tumors. The company utilizes its proprietary technology to overcome the limitations of traditional cell therapies in treating solid malignancies, such as poor infiltration and the immunosuppressive microenvironment. Its lead program, BD-001, targets Claudin 18.2 and is currently in Phase 1 clinical trials for indications including gastric and pancreatic cancers. Beyond its lead asset, the company is advancing a pipeline of candidates targeting Mesothelin and Glypican 3. Beidou Biotechnology is committed to advancing the field of immunotherapy through rigorous scientific innovation and clinical validation.